Wuxi PharmaTech Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the US, announced that it has acquired NextCODE, a leading genomic analysis and bioinformatics company with operations in the US and Iceland, for $65 million. WuXi plans to merge NextCODE Health and WuXi’s Genome Center into a new company to be named WuXi NextCODE Genomics. The business will be headquartered in Shanghai, with operations in Massachusetts and Iceland.
This acquisition lays the groundwork for the creation of an integrated global enterprise with unique advantages for applying genomics to medicine. It broadens and enhances WuXi’s existing genomic laboratory services for biopharmaceutical research and clinical development, as well as NextCODE’s unique capabilities in genome analysis. It provides global commercial customers of both entities with comprehensive genomic and bioinformatic capabilities, from CLIA-certified whole genome and whole exome sequencing to the analysis and interpretation of that sequencing data necessary to provide effective diagnosis and treatment.
Read more at: http://www.wuxiapptec.com/press/detail/259/18.html